Portfolio company
Convert Pharmaceuticals
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops hypoxia-activated prodrugs that transform into anti-cancer agents to treat patients with solid tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
TwoStep Therapeutics
The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.
Cybrexa
The company develops peptide-drug conjugate therapeutics for oncology patients to deliver anti-cancer agents directly into tumours using a pH-sensitive targeting platform.
Promatix
Promatix develops antibody-drug conjugates for cancer treatment using a proprietary multi-omics platform to identify and target specific tumour markers.
Taveren Therapeutics
The company develops oncology drug candidates that reactivate natural tumour suppressors for pharmaceutical partners and cancer patients.
1200 Pharma
This biotechnology firm develops small molecule therapies and drug intellectual property for the treatment of cancer patients.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
Halda
This biopharmaceutical company develops proximity-targeting small molecule therapies to treat patients with solid tumours including prostate and breast cancers.
Cage Pharmaceuticals
This biopharmaceutical company develops drugs targeting tumor metabolism and glycolysis to treat cancer patients.